According to the results of a new study, “cannabis-based medicines may be effective in treating the pain and symptoms of ...

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

ANP-390 is under clinical development by AlphaNavi Pharma and currently in Phase I for Peripheral Neuropathic Pain.

Lidocaine patches or a topical cream called capsaicin, which can be helpful for small, painful areas, block nerve conduction and can be used as a treatment for peripheral neuropathy. TENS machine ...

Although systematic reviews have outlined the current treatment options for neuropathic ... but NNTs were calculated for many peripheral neuropathic pain conditions. The NNT for tricyclic ...

Introduction Available therapies for peripheral nerve injury (PNI) include surgical and non-surgical treatments. Surgical treatment includes neurorrhaphy ... Using a systematic review and NMA, we ...

which is dermatomal pain persisting at least 90 days after the appearance of an acute herpes zoster rash. Postherpetic neuralgia often becomes chronic and resistant to standard treatments; this can ...

Injured peripheral nerve fibers give rise ... the power to detect a positive treatment result. An increased knowledge of the mechanisms underlying pain and their translation into signs and ...

Shares of Vertex Pharmaceuticals Incorporated VRTX were down 11.4% yesterday after the company announced data from a phase II ...

Peripheral artery disease is the narrowing and blocking of the arteries in the legs. This process of furring up of the blood ...